Chronic Granulomatous Disease: The European Experience by van den Berg, J. Merlijn et al.
Chronic Granulomatous Disease: The European
Experience
J. Merlijn van den Berg
1*, Elsbeth van Koppen
1, Anders A ˚hlin
2, Bernd H. Belohradsky
3, Ewa
Bernatowska
4, Lucien Corbeel
5, Teresa Espan ˜ol
6, Alain Fischer
7, Magdalena Kurenko-Deptuch
4, Richard
Mouy
8, Theoni Petropoulou
9, Joachim Roesler
10, Reinhard Seger
11, Marie-Jose ´ Stasia
12, Niels H.
Valerius
13, Ron S. Weening
1, Baruch Wolach
14, Dirk Roos
1, Taco W. Kuijpers
1
1Sanquin Research, and Landsteiner Laboratory, Emma Children’s Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands, 2The
Department of Clinical Science and Education, Sodersjukhuset, Sachs’ Children’s Hospital, Karolinska Institutet, Stockholm, Sweden, 3Dr v. Haunersches Kinderspital,
Ludwig Maximilians University, Munich, Germany, 4Department of Immunology, The Children’s Memorial Health Institute, Warsaw, Poland, 5Department of Pediatrics,
University Hospital, Leuven, Belgium, 6Immunology Department, Vall d’Hebron Hospital, Barcelona, Spain, 7Universite ´ Rene ´ Descartes-Paris 5, Ho ˆpital Necker-Enfants
Malades, Paris, France, 8Unite ´ d’Immunologie et d’He ´matologie Pe ´diatrique, Ho ˆpital Necker-Enfants Malades, Paris, France, 91st Department of Pediatrics, University of
Athens, Aghia Sophia Children’s Hospital, Athens, Greece, 10Department of Pediatrics, University Clinic Carl Gustav Carus, Dresden, Germany, 11Division of Immunology/
Hematology/BMT, University Children’s Hospital, Zurich, Switzerland, 12Centre diagnostic et recherche sur la granulomatose septique, TIMC/Imag, UMR CNRS 5525,
Universite ´ Joseph Fourier, CHU de Grenoble, Grenoble, France, 13Department of Pediatrics, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark,
14Department of Pediatrics and Laboratory for Leukocyte Functions, Meir Medical Center, Kfar Saba, Israel
Abstract
CGD is an immunodeficiency caused by deletions or mutations in genes that encode subunits of the leukocyte NADPH
oxidase complex. Normally, assembly of the NADPH oxidase complex in phagosomes of certain phagocytic cells leads to a
‘‘respiratory burst’’, essential for the clearance of phagocytosed micro-organisms. CGD patients lack this mechanism, which
leads to life-threatening infections and granuloma formation. However, a clear picture of the clinical course of CGD is
hampered by its low prevalence (,1:250,000). Therefore, extensive clinical data from 429 European patients were collected
and analyzed. Of these patients 351 were males and 78 were females. X-linked (XL) CGD (gp91
phox deficient) accounted for
67% of the cases, autosomal recessive (AR) inheritance for 33%. AR-CGD was diagnosed later in life, and the mean survival
time was significantly better in AR patients (49.6 years) than in XL CGD (37.8 years), suggesting a milder disease course in AR
patients. The disease manifested itself most frequently in the lungs (66% of patients), skin (53%), lymph nodes (50%),
gastrointestinal tract (48%) and liver (32%). The most frequently cultured micro-organisms per episode were Staphylococcus
aureus (30%), Aspergillus spp. (26%), and Salmonella spp. (16%). Surprisingly, Pseudomonas spp. (2%) and Burkholderia
cepacia (,1%) were found only sporadically. Lesions induced by inoculation with BCG occurred in 8% of the patients. Only
71% of the patients received antibiotic maintenance therapy, and 53% antifungal prophylaxis. 33% were treated with c-
interferon. 24 patients (6%) had received a stem cell transplantation. The most prominent reason of death was pneumonia
and pulmonary abscess (18/84 cases), septicemia (16/84) and brain abscess (4/84). These data provide further insight in the
clinical course of CGD in Europe and hopefully can help to increase awareness and optimize the treatment of these patients.
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Introduction
Chronic granulomatous disease (CGD) is an uncommon
inherited immunodeficiency, occurring in about one in 250,000
individuals. Although the genetic basis for this disease is well-
known, the expected clinical course and outcome have only
partially been defined, owing to its sporadic occurrence [1–3].
There are extreme differences in presentation between patients,
varying form a relatively mild presentation late in life to fatal
septicemia in infancy. This renders it difficult for clinicians to
inform CGD patients and their parents what to expect, and to find
a proper balance between risks, costs and benefits of various
treatments, ranging from long-term prophylactic antibiotic
medication to stem cell transplantation and gene therapy [4].
CGD is caused by a defect in the burst of oxygen consumption
that normally accompanies phagocytosis in myeloid cells (i.e.
neutrophils, eosinophils, monocytes, and macrophages). The
‘‘respiratory burst’’ involves the catalytic conversion of molecular
oxygen to the oxygen free-radical superoxide (O2
2), which in turn
gives rise to hydrogen peroxide (H2O2), hypochlorous acid
(HOCl), and hydroxyl radical (
.OH). These oxygen derivatives
play a critical role in the killing of certain pathogenic bacteria and
fungi. As a result of the failure to mount a respiratory burst in their
phagocytes, the majority of CGD patients suffers from severe
recurrent infections and also from dysregulated Th-17-lympho-
cyte-controled inflammation [5] Therefore, CGD patients can
develop diffuse granulomas that can become sufficiently large to
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ureters, or urinary bladder, or dysfunctional disorders secondary
to extensive fibrosis of the different systems (pulmonary,
gastrointestinal, genitourinary, central nervous system) [6–9].
Also, autoimmune phenomena have been reported to occur at
an increased incidence rate in CGD patients and in female X-
linked carriers [10–12].
The enzyme that catalyzes the respiratory burst, the leukocyte
NADPH oxidase, consists of subunits, four of which are important
for CGD (designated phox for phagocyte oxidase): gp91
phox (or
Nox2) and p22
phox, located in membranes, as well as two cytosolic
oxidase components, p47
phox and p67
phox. CGD is caused by a
defect in any of these four components. Mutations in the gp91
phox
gene (CYBB on chromosome Xp21.1) cause the X-linked recessive
form of the disease that affects the majority of CGD patients
(,70%). As expected from the genetics, the overwhelming
majority of X-linked patients are males. The remaining 30% of
cases has inherited the disease in an autosomal recessive manner,
in which males and females are equally affected. These patients
have mutations in the genes encoding p47
phox (NCF1 on
chromosome 7q11.23), p67
phox (NCF2 on chromosome 1q25), or
p22
phox (CYBA on chromosome 16q24). In contrast to p47
phox
deficiency [13], most CGD patients with any of the other three
forms have mutations unique to their families [14].
Apart from the description of several smaller cohorts, the first
characterization of a large group of CGD patients was published
by Winkelstein et al., who reported on a national American
registry of 368 patients [1]. To further improve knowledge of the
course of CGD, clinical data from European patients were
collected. We now report our findings in 429 European patients,
the largest cohort of CGD patients to date.
Methods
In most European countries, diagnostic tests for CGD are
traditionally performed by a small number of specialized institutes.
The clinical heads of these institutes were asked to collect data
from the medical charts of their CGD patients, by means of an
extensive questionnaire. (Participating institutes: Emma Children’s
Hospital, Academic Medical Centre, Amsterdam, The Nether-
lands; Sachs’ Children’s Hospital, Karolinska Institutet, Stock-
holm, Sweden; Dr v. Haunersches Kinderspital, Munich,
Germany; The Children’s Memorial Health Institute, Warsaw,
Poland; Department of Pediatrics, University Hospital, Leuven,
Belgium; Vall d’Hebron Hospital, Barcelona, Spain; Universite ´
Rene ´ Descartes-Paris 5, Ho ˆpital Necker-Enfants Malades, Paris,
France; Unite ´ d’Immunologie et d’He ´matologie Pe ´diatrique,
Ho ˆpital Necker-Enfants Malades, Paris, France; University Clinic
Carl Gustav Carus, Dresden, Germany; University Children’s
Hospital, Zurich, Switzerland; Centre diagnostic et recherche sur
la granulomatose septique, Universite ´ Joseph Fourier, Grenoble,
France; Dept of Pediatrics, Copenhagen University Hospital
Hvidovre, Denmark; Department of Pediatrics and Laboratory
for Leukocyte Functions, Meir Medical Center, Kfar Saba, Israel).
Approval was obtained from the medical ethical committee of the
Academical Medical Center in Amsterdam, The Netherlands.
Informed consent forms were signed by those patients who were
alive and not lost to follow up. The answers on the completed
questionnaire of each individual patient were subsequently
translated to a database and analyzed. Prior to analysis, the
patients’ information was completely anonymized. The data were
collected between the years 2000–2003.
In total, questionnaires of 446 patients were sent in, of which 17
were eventually omitted because of incomplete data, resulting in
429 individuals analyzed. The oldest clinical information dated
from 1954, the most recent from 2002.
The diagnosis of CGD was established in all 429 patients by
means of several well-described diagnostic tests, such as the
nitroblue tetrazolium assay (NBT) or the dihydrorhodamine-1,2,3
(DHR) test [15–16]. In the majority of patients, the diagnosis was
confirmed by Western blot, showing the absence of one of the
NADPH oxidase components, and DNA analysis on blood
samples of the patient or his relatives [17]. Determination of the
CGD subtype was also performed by means of Western blot and/
or DNA analysis. However, in some cases, deceased relatives of
proven CGD patients, who had previously died from unexplained
overwhelming infection or granulomatous disease, were included
(i.e., maternal uncles or siblings from affected ‘‘established’’
patients).
Of female patients in which the diagnosis CGD had been
established by adequate laboratory analysis, but the subtype had
not been established by Western blot or DNA sequencing, it was
assumed they were suffering from an autosomal recessive form of
the disease (20 cases). Deficiency of gp91
phox in females, leading to
clinical CGD, can only be caused by extremely unfavorable
lionization [18], which is very rare. In 17 male patients, the exact
subtype of CGD was not established, but either the presence of
gp91
phox was shown by Western blot, or the family history strongly
suggested an autosomal recessive mode of inheritance. This led to
the conclusion that these patients also suffer from AR-CGD.
Results
1. Population
The origin of the patients was categorized according to the
country of residence or alternatively to the country of origin of the
parents when this information was provided. Of 438 patients, the
largest group were French (84), followed by Germans (69), Dutch
(62), immigrants from Arab/ North African descent (38), Poles
(30), Spaniards (25), Swedes (24), Swiss (24), Danes (22), Israeli/
Jewish (16), immigrants from Turkey (12), (former) Yugoslavs (8),
Belgians (6), immigrants from miscellaneous Asian countries (6),
Italians (2) and Austrians (1) (Table 1). Patients in the Arab/North
African group were living in several European countries, but also
included 6 individuals form Arab descent living in Israel, the
remainder of the Israeli group being of Jewish origin.
Conspicuously absent in this database were patients from the
United Kingdom, Ireland and Italy. In these countries national
registries of the clinical data from CGD patients were being
constructed independently, the data of which have recently been
published separately [2–3]. One remarkable observation is the
high prevalence of the autosomal recessive forms of CGD in
immigrant groups from Arab/ North African countries (71%) and
Turkey (67%), reflecting consanguineous marriage practices
common within these communities.
Of the 429 patients, 351 were male (82%) and 78 female (18%),
including 6 heterozygous female carriers with an extremely
unfavorable lyonization (Table 2) [19]. This corresponds with
the data known from earlier publications [1].
Within the AR-CGD subgroup, deficiency of p47
phox was most
prevalent (49%), as was the case in the American CGD cohort [1],
followed by p22
phox (16%) and p67
phox (8%) (Table 3).
2. Clinical course
The diagnosis CGD was established usually early in life
(Figure 1). However, the mean age at diagnosis (Figure 2;
Table 4) was higher in the AR CGD group (8.8 years) than in
X-linked CGD (4.9 years) (p,0.001, as assessed by Mann-
CGD: The European Experience
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5234Whitney U analysis). This probably reflects a milder phenotype of
AR-CGD, and hence an extensive immunological work-up at a
later age, and not a bias towards earlier screening of boys for
CGD. The mean age at diagnosis of AR-CGD in boys was even
higher than in girls (10.0 vs 7.7 years). Another possible
explanation could be more adequate screening of possibly affected
boys in extended families with X-linked CGD, leading to very
early diagnosis (e.g. at birth) before any signs of the disease have
become manifest.
At the time of data collection 84 patients had died (20%). Of
331 individuals, the last known date when the patient was reported
to be alive was used for statistical analysis. 14 patients were
excluded because of the lack of reliable data.
Clearly, AR patients were not only diagnosed later, but a higher
percentage had survived up to the time of inclusion in this cohort.
Also, the age at death and the mean survival time were much
higher in the AR group (Table 4). Statistical analysis, as reflected
in Figure 3, showed that this difference was highly significant
(p=0.0081). These data confirm the widely held conviction that
AR-CGD follows a milder course than XL-CGD.
Table 1. The cohort of CGD patients divided according to
nationality/ ethnic background and type of CGD.
Country/ Region of Origin Total CGD type
X-linked AR*
France 84 75 (89%) 9 (11%)
Germany 69 54 (78%) 15 (22%)
The Netherlands 62 43 (69%) 19 (31%)
Arab/North African 38 11 (29%) 27 (71%)
Poland 30 21 (70%) 9 (30%)
Spain 25 16 (64%) 9 (36%)
Sweden 24 12 (50%) 12 (50%)
Switzerland 24 19 (79%) 5 (21%)
Denmark 22 12 (55%) 10 (45%)
Israeli/Jewish 16 9 (56%) 7 (44%)
Turkey 12 4( 33%) 8 (67%)
Former Yugoslavia 8 7 (88%) 1 (12%)
Belgium 6 5 (83%) 1 (17%)
East and South Asia 6 1 (17%) 5 (83%)
Italy 2 11
Austria 1 01
Total 429 290 (67%) 139 (33%)
*AR=autosomal recessive.
doi:10.1371/journal.pone.0005234.t001
Table 2. Distribution of different subtypes of CGD according
to sex.
Male Female Total
X-linked 284 (81%) 6 (8%)*2 9 0 (67%)
AR 67 (19%) 72 (92%) 139 (33%)
Total 351 (82%) 78 (18%) 429
*Female X-linked patients are extremely lyonized heterozygous carrriers.
doi:10.1371/journal.pone.0005234.t002
Table 3. Different subtypes of autosomal recessive CGD.
AR type Male Female Total
p47 38 (57%) 31 (42%) 69 (49%)
p22 10 (15%) 12 (16%) 22 (16%)
P67 2 (3%) 9 (13%) 11 (8%)
Unknown 17 (25%) 20 (28%) 37 (27%)
Total 67 72 139
doi:10.1371/journal.pone.0005234.t003
Figure 1. The age at diagnosis of CGD, irrespective of the
subtype. Each column represents 2.5 years.
doi:10.1371/journal.pone.0005234.g001
Figure 2. Average Age at Establishment of Diagnosis ‘‘CGD’’.
doi:10.1371/journal.pone.0005234.g002
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The most prevalent site of disease, be it infectious or
granulomatous, were the lungs, followed by skin/subcutis, lymph
nodes, gastro-intestinal tract and liver (Table 5). These findings
confirm earlier reports and general assumptions on the clinical
presentation of CGD [1–3]. From the data collected, it was not
possible to adequately determine the first symptom or site of
disease at presentation.
Pulmonary involvement (634 episodes in 284 patients, 66% of
the total population) most frequently consisted of pneumonia (597
episodes) and rarely of lung abscess (26 episodes in 24 patients)
(Table 6). Pulmonary granulomatous disease, as defined by a
histological diagnosis and negative culture, was only proven in 11
episodes in 10 patients. This presentation of CGD is sometimes
initially confused with mycobacterial infection or sarcoidosis [9].
The most frequently isolated microorganism was Aspergillus spp.
(111 cases), other pathogens were rarely seen. Sporadic cases
included Cephalosporium (26), Streptococcus pneumoniae (26), Scedospor-
ium [20] (16), Paecilomyces [21] (16), Phialophora richardsiae (16),
Rhodococcus equi [22] (16) and Staphylococcus epidermidis (16). Some of
these rare pathogens have been described in earlier reports to
cause infection in CGD.
Remarkably rare in this cohort was Burkholderia cepacia,a
pathogen frequently described to have caused fulminant pneumo-
nia in CGD [1,23]. The low number of positive cultures for
Pseudomonas spp. (3) excludes the possibility that a significant
number of B. cepacia isolates could have been described as
Pseudomonas (B. cepacia was previously known as Pseudomonas cepacia).
However, in the majority of episodes the causative pathogen could
not be isolated.
After the lungs, the skin is the most frequently affected site of
disease (Table 7). The etiology is diverse, ranging from abscesses in
the skin to aseptic granulomas. Discoid lupus erythematodes
(DLE) is not included in this section (vide infra). When cultures were
performed, S. aureus was most prominent. Occasional pathogens
found in skin abscesses (131 cases) included S. epidermidis (36),
Serratia marcescens (26), Proteus mirabilis (26), Escherichia coli (26) and
Klebsiella pneumoniae (16).
Vaccination with Bacille Calmette-Gue ´rin (BCG) resulted in
subsequent localized skin infection in 24 patients (BCG-itis). In
Table 4. Clinical course in CGD.
XL AR
Avg. age at diagnosis (years) 4.9 (range: a.n
+.- 43 yrs) 8.8 (range: a.n.- 54 yrs)
Deceased
" 64/279 (23%) 20/136 (15%)
Median age at time of death (years) 8.8 (range: 0.16–34.5) 10.4 (range: 1.1–54.8)
Mean survival time (years) 37.8 49.6
Clinical course in CGD patients is milder in AR patients, as reflected by a later age at diagnosis and longer survival.
+a.n.=antenatal.
"14 out of 429 patients were excluded because reliable data on survival were lacking.
doi:10.1371/journal.pone.0005234.t004
Figure 3. Cumulative survival of AR patients compared to XL patients. *Log rank statistics for difference in survival between X-linked and AR:
7.01 (p=0.0081).
doi:10.1371/journal.pone.0005234.g003
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suffering from lymphadenitis (Table 8). Thus, BCGitis occurred in
34/429 patients (8%). There was no association between the
occurrence of BCGitis with CGD type (AR or XL), nor with sex. A
remarkably high percentage of this group was living in France
(22=65%). As a whole, the French cohort in this database
consisted of 100 individuals, 84 of which were of French ancestry
and 16 originated from other countries, mainly from North Africa.
Thus, 22% of the French patients developed BCGitis at one point
in time during their lives. This group included 18 ethnic French,
two Arabs and two individuals of Asian descent, suggesting that
not ethnic differences, but rather exposure was the cause of this
high incidence. BCG vaccination was given routinely to all French
children until recently, whereas other European countries only
vaccinate children with an increased risk of being infected with
tuberculosis (e.g. children of immigrants traveling to their home
countries). Susceptibility to Mycobacterium tuberculosis or atypical
mycobacteria was not clearly increased. Recently, a number of
reports, some of which have so far not been published, have
claimed there is indeed an increased susceptibility for mycobac-
terial infection in CGD [24–25].
Again, in lymphadenitis, a frequent manifestation of CGD, in
most episodes no causative pathogen was isolated, either because
cultures were negative or because a fine needle aspirate or biopsy
had not been performed (80%, Table 8). S. aureus was cultured
most frequently, as was expected. Sporadically, lymphadenitis was
caused by Actinomyces (16), Haemophilus influenzae (16), Philalophora
richardsiae (16) and P. mirabilis (16). Vaccination with BCG
resulted in regional lymphadenitis in 7 individuals (see above).
CGD can manifest itself in the gastrointestinal tract from the
oral cavity to the anus (Table 9) [8]. Although gastrointestinal
symptoms occurred even more often than pulmonary symptoms
(643 vs 634 episodes), the number of patients who had suffered
from one or more gastrointestinal symptoms was lower (48% vs
66%). Apart from non-typhoid Salmonella spp. gastroenteritis, no
relevant other microorganisms were cultured from stool samples or
biopsies. Granulomatous disease was frequently found in the
gastrointestinal tract, ranging from esophageal and pyloric
obstruction caused by granulomas to granulomatous disease of
the colon mimicking the clinical presentation of Crohns colitis. In
26 out of 66 cases of suspected colitis, the diagnosis was reported to
have been confirmed by colonoscopy and histology of biopsies.
Appendicitis, although often cited as one of the presenting signs of
intestinal granuloma formation in young CGD patients, is rare in
this cohort, not exceeding the prevalence in the healthy
population.
240 episodes of liver abscess were seen in 138 patients (32% of
total), most frequently caused by S. aureus (25%), as expected
(Table 10).
In 23% of the patients involvement of the kidneys or the urinary
tract was seen, sometimes leading to renal insufficiency (Table 11).
Although infection is the most common manifestation of urinary
tract involvement, more serious complications are found when
obstruction by granulomata causes hydronephrosis or obstruction
of the ureter, bladder or urethra [7], which was found in 6% of the
patients.
Septicemia was seen in 20% of the patients (111 episodes in 85
patients), most frequently caused by Salmonella spp., followed by S.
aureus (Table 12). Miscellaneous causative bacteria included Listeria
Table 5. Site of disease.
Site of Disease
Number of
episodes
Number of
patients with
$1 episode
% of patients
with $1
episode
Lung 634 284 66%
Skin/ Subcutis 341 229 53%
Lymph node 622 213 50%
Gastro-intestinal 643 208 48%
Liver 240 138 32%
Kidney/ Urinary tract 139 95 22%
Septicaemia 111 85 20%
Ear 84 62 14%
Bone 84 56 13%
Eye 68 46 11%
Joint 35 31 7%
Brain 34 31 7%
Autoimmunity-
Rheumatology
26 26 6%
The total number of reported episodes in all patients is compared to the
number of patients who has suffered from $1 episode in absolute numbers
and percentage of the total group (n=429).
doi:10.1371/journal.pone.0005234.t005
Table 6. Pulmonary involvement and cultured microorganisms.
Pneumonia Lung Abscess Granulomatous Total
Number of episodes 597 26 11 634
Cultured micro-organism:
Aspergillus spp. 111 (18%) Klebsiella spp. 4
Candida spp. 10 (2%) Pseudomonas spp. 3
S. aureus 10 (2%) Streptoccus viridans 3
H. influenzae 6( ,1%) Actinomyces 2
M. tuberculosis 5 Acremonium 2
Atypical Mycobacteria 3 Misc. 9
Nocardia spp. 4
Negative culture/ not done 454 (72%)
Pulmonary involvement and cultured microorganisms (in total 634 episodes in 284 patients). Percentages are the number of episodes with a positive culture of a certain
pathogen divided by the total number of reported episodes.
doi:10.1371/journal.pone.0005234.t006
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enterocolitica (all 1 case).
Otitis media was found in 14% of the patients (84 episodes in 62
patients, not shown). In 89% of the episodes, no cause of the otitis
was identified, the remaining episodes being caused by P. aeruginosa
(56), S. aureus (16), Streptococcus viridans (16) and K. pneumoniae (16).
Osteomyelitis, seen in 84 episodes in 56 patients (13%), was
caused mostly by Aspergillus spp., followed by Serratia marcescens,
confirming earlier data [1]. Sporadic episodes included S.
epidermidis (2 episodes), Providencia and Nocardia (all 1 case)
(Table 13). The most frequently affected bones were the ribs (15
episodes), vertebrae (8 episodes), femur (7 episodes), talus (6
episodes) and tibia (5 episodes). The bones of the hand, thought to
be a predilection location for osteomylitis in CGD, were only
affected in 4 cases in this cohort.
The eyes were involved in 11% of the patients (68 episodes in 46
patients, not shown). Conjunctivitis was the most prevalent (21
cases), without identified organisms, as was the case with
blepharitis (5 cases). Chorioretinitis, a well known but not well
understood feature also found in other immunodeficiencies, was
seen in 8 patients [26].
Septic arthritis accounted for 36 episodes in 32 patients (8%)
(table not shown). However, only in the minority of episodes a
pathogen was cultured, mostly S. aureus (4), followed by Serratia spp.
(3), Aspergillus spp. and Nocardia (both 1 episode).
Table 14 shows the prevalence of brain abscesses, a most feared
complication of CGD (see below). Thirty-one patients (7%; 34
episodes) developed a brain abscess, mostly caused by Aspergillus
spp.
With all infectious episodes taken together, the most frequently
cultured microorganism was S. aureus (30%), followed by Aspergillus
Table 7. Diseases of the skin in CGD and causative pathogens.
Abscess Dermatitis Acne Furunculosis BCGitis Granuloma Total
Number of episodes 131 101 29 39 24 11 341
Number of patients with $1 episode 74 71 25 21 24 10 229
% of patients with $1 episode 17% 17% 7% 5% 6% 2% 53%
Most frequently cultured microorganisms
Abscess Dermatitis Furunculosis
S. aureus (12%) S. aureus (17%) S.aureus (14%)
Aspergillus spp. (5%) Candida spp. (5%)
S. epidermidis (5%)
Serratia marcescens (3%)
doi:10.1371/journal.pone.0005234.t007
Table 8. Lymphadenitis.
Number of episodes 622 in 213 patients
Cultured micro-organism:
S. aureus 76 (12%) B. cepacia 4
S. marcescens 11 (2%) Aspergillus spp. 3
Post-BCG 10 (2%) Candida spp. 3
S. epidermidis 8 (1%) M. tuberculosis 2
Klebsiella spp. 6( ,1%) Salmonella spp. 2
Atypical Mycobacteria 5 Misc. 4
Negative culture/ not done 495 (80%)
Lymphadenitis and cultured micro-organisms (in total 622 episodes in 213
patients). Percentages are the number of episodes with a positive culture of a
certain pathogen divided by the total number of reported episodes.
doi:10.1371/journal.pone.0005234.t008
Table 9. Gastrointestinal manifestations of CGD.
Number of episodes
Number of patients with $1
episode % of patients with $1 episode
Gastroenteritis (50% Salmonellosis) 140 112 26%
Peri-anal abscess/ fissure 145 88 21%
Diarrhea 71 55 13%
Stomatitis 66 48 11%
Aphthae 58 48 11%
Gingivitis/ Caries 51 47 11%
Colitis (38% granulomatous) 66 40 9%
Pyloric outlet obstruction 16 9 2%
Esophageal granuloma/obstruction 11 9 2%
Appendicitis 772 %
Pancreatitis 861 %
doi:10.1371/journal.pone.0005234.t009
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occurring rather seldom or even sporadically (Table 15). These
findings roughly reflect previous data. However, the relatively low
number of isolates of Burkholderia cepacia is remarkable, seen in the
light of earlier reports.
Manifestations of autoimmunity or autoinflammation have been
claimed to be more prevalent in CGD patients than in the normal
population. Mothers of boys with X-linked CGD, themselves
carriers, are known to be prone to lupus or lupus-like skin lesions,
such as discoid lupus erythematodes [12]. In this cohort, signs of
autoimmune disease were seen in 26 patients (6%), indeed mostly
discoid lupus (18 cases). Other manifestations were sporadic,
including rheumatoid arthritis (2 cases), systemic lupus erythema-
todes, dermatomyositis, sacroiliitis, idiopathic thrombocytopenia
and autoimmune hepatitis (all 1 case). Thus, apart from discoid
lupus, of which the estimated prevalence in the general population
is much lower than in this cohort, other signs of autoimmunity or
rheumatic disorders seem to be no more prevalent than in healthy
individuals (not shown).
4. Prophylactic and curative therapies
Most CGD patients are treated with long-term, low-dose
antibiotics and antifungals [27]. In this cohort, 71% of the
patients were reported to use antibiotic prophylaxis at at least one
point of their clinical history, mostly co-trimoxazole (Table 16).
Antifungals had been used by 53%, mostly itraconazole.
Interferon-c by subcutaneous injection up to 3 times a week has
been given to many patients after a trial had shown a protective
result against infection [28]. A true understanding of the positive
effect of IFN-c on neutrophil biology or innate immunity in
general is still lacking. Combined with side effects in some patients,
this has prompted many clinicians to administer IFN-c to some,
but not all patients. In this cohort, 33% of all patients had at some
point received IFN-c. Unfortunately, it was not possible from the
collected data to link long-term maintenance therapies, be it
antibiotics, antifungals or IFN-c, with the occurrence of infection,
complications, or death.
Granulocyte transfusions are increasingly given to CGD
patients when traditional therapies fail to resolve life-threatening
infections, especially with Aspergillus spp. [29]. Seven percent of the
patients received a granulocyte transfusion at one point.
A curative therapy for CGD is stem-cell transplantation.
However, this treatment has a considerable risk of transplanta-
tion-related morbidity and mortality, especially in patients with
severely compromised pulmonary function or other debilitating
illnesses [30]. In this cohort, 24 patients (6%) had been treated
with stem-cell transplantation, of whom 5 had died at the time of
inclusion. No patients in this cohort had at the time of inclusion
been treated with gene therapy. This treatment had a promising,
though transient, clinical effect in some selected patients [31], but
insertional mutagenesis also bears new risks.
5. Cause of death
As mentioned above, 84 patients had died before the time of
inclusion (20%) (Table 4, Table 17). The largest number of
patients had died from pneumonia, with a particular increased risk
from aspergillosis. Septicemia was the cause of death in another 16
patients. Although Burkholderia cepacia did not account for a high
number of infectious episodes in this cohort, a relatively high
number of patients died from septicemia with this pathogen (3),
illustrative of the possible fulminant nature of Burkholderia cepacia
infection. Aspergillus spp. was again the most prominent pathogen to
cause death in patients with a brain abscess. Only one patient died
of malignancy (malignant melanoma). In this cohort, three patients
Table 10. Prevalence of liver abscess and causative micro-
organisms.
Number of episodes 240 in 138 patients (32%)
Cultured micro-organism:
S. aureus 59 (25%) Candida spp. 1( ,1%)
Aspergillus spp. 6 (3%) Streptococcus milleri 1
S. marcescens 5 (2%) Enterobacter cloacae 1
Negative culture; 167 (70%)
doi:10.1371/journal.pone.0005234.t010
Table 11. Involvement of kidneys and urinary tract (UT).
Urinary tract infection*
Granulomata (causing
UT obstruction) Renal insufficiency Total
Number of episodes 77 44 18 139
Number of patients with $1 episode 52 25 18 98
% of patients with $1 episode 12% 6% 4% 23%
Most frequently cultured micro-organisms in UTI
E. coli(13%) Salmonella spp. (4%)
P. mirabilis (5%) K. pneumoniae (4%)
*including three episodes of renal abscess.
doi:10.1371/journal.pone.0005234.t011
Table 12. Prevalence and causes of septicemia.
Number of episodes 111 episodes in 85 patients
Cultured micro-organism:
Salmonella spp. 36 (32%) B. cepacia 3 (3%)
S. aureus 11 (10%) Pseudomonas spp. 2 (2%)
S.epidermidis 6 (5%) K. pneumoniae 2 (2%)
Aspergillus spp. 4 (4%) E. coli 2 (2%)
Candida spp. 3 (3%) S. marcescens 1 (1%)
Streptococcus spp. 3 (3%) Misc. 5 (5%)
Negative culture 23 (21%)
doi:10.1371/journal.pone.0005234.t012
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lymphoma. This does not point to a clear, significantly increased
risk for malignant disease in CGD patients.
Discussion
This is the largest cohort of CGD patients described so far. It
combines clinical data collected from most of the prominent
centers on the European continent that have dealt with the
diagnosis and treatment of CGD for several decades. From the
huge amount of clinical information collected, the most relevant
data are presented here.
It is still not possible to determine the true incidence and
prevalence of CGD. From this cohort one would discern that in
the Netherlands the prevalence of CGD is high (62 cases on a
population of 16 million), and even higher in Denmark (22 cases
on a population of 5.5 million). Most likely these numbers are due
to a high awareness of the disease. This view is supported by the
observation that more cases of CGD are found when laboratory
diagnostic tools are improving [3].
A weakness of this cohort is the absence of patients from two
large European countries, the UK and Italy [2–3]. Also, clinical
data from many Central and Eastern European countries have not
been added to the present database. Another problem is the
quality of older data, a common challenge in the analysis of
retrospective databases. In order to improve the clinical data
analysis of CGD patients, many data from other countries will
Table 13. Prevalence and causes of osteomyelitis.
Number of episodes 84 cases in 56 patients
Cultured micro-organism:
Aspergillus spp. 29 (35%) S. epidermidis 2 (2%)
Serratia spp. 7 (8%) Salmonella spp. 2 (2%)
S. aureus 3 (4%) Enterobacter spp. 2 (2%)
Negative culture; unknown 37 (44%) Misc. 2 (2%)
doi:10.1371/journal.pone.0005234.t013
Table 14. Prevalence and causes of brain abscess.
Number of episodes 34 episodes in 31 patients
Cultured micro-organism:
Aspergillus spp. 13 (38%) Klebsiella spp. 1 (3%)
Salmonella spp. 2 (6%) S. aureus 1 (3%)
Negative culture; unknown 17 (50%)
doi:10.1371/journal.pone.0005234.t014
Table 15. Most frequently isolated micro-organisms.
Cultured micro-organism No % of total
S. aureus 210 30%
Aspergillus spp. 181 26%
Salmonella spp. 110 16%
Candida spp. 45 6%
Serratia spp. 31 4%
S. epidermidis 22 3%
Klebsiella spp. 14 2%
Pseudomonas spp. 11 2%
M. tuberculosis 81 %
Atypical Mycobacteria 81 %
H. influenzae 6 ,1%
B. cepacia 7 ,1%
Streptoccus spp. 7 ,1%
Nocardia 4 ,1%
Misc. 37 5%
Total 701
doi:10.1371/journal.pone.0005234.t015
Table 16. Prophylactic and curative treatment.
Type of treatment % Patients who received treatment
Antibiotic prophylaxis 71%
Of which: Co-trimoxazole 42%
Ciprofloxacin 4%
Clindamycin 3%
Rifampicin 3%
Antifungal prophylaxis 53%
Of which: Itraconazole 47%
Amphotericin B 15%
Ketoconazole 7%
Interferon-c 33%
Granulocyte Transfusion 7% (326)
Stem cell transplantation 6% (246)
Percentages of patients who received above-mentioned therapies at one point
during their lives.
doi:10.1371/journal.pone.0005234.t016
Table 17. Cause of death.
Number of deceased patients: 84 (20%)
Pneumonia: 18 (21%) Of which: Aspergillus spp.:1 2
Bacterial n.o.s*.: 6
Septicemia: 16 (19%) Of which: n.o.s. :10
Burkholderia cepacia:3
Salmonella spp.:2
Candida spp.:1
Brain abscess: 4 (5%) Of which: Aspergillus spp.:3
Bacterial n.o.s.: 1
Cardiac Failure 3 (4%)
Chronic Lung Disease 2 (2%)
Liver Abscess 2 (2%)
Post BMT 2 (2%)
Malignancy 1 (1%)
Miscelaneous 5 (6%)
Unknown 31 (37%)
*n.o.s.=not otherwise specified.
doi:10.1371/journal.pone.0005234.t017
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has to be warranted. These issues will be addressed by a new on-
line, prospective, clinical registry for European patients that is
currently under construction by the European Society for Immune
Deficiencies (ESID).
Because of the retrospective nature of the current database, it
was not possible to clearly define at what time point exactly the
patients suffered from the different afflictions characteristic of
CGD. Thus, the effect of prophylactic treatment could not be
analyzed. Although the use of antibiotic prophylaxis in CGD
patients is undisputed, with antifungal prophylaxis, side-effects of
itraconazole (which is routinely used) and the burden of taking life-
long daily drugs will have to be compared to the effect of prompt
and effective therapeutic treatment when fungal infection is
suspected in patients who do not take antifungal prophylaxis.
Newer antifungal drugs such as posaconazole might be more
beneficial, as they are believed to cause less side effects. Also, the
evidence that interferon-gamma helps prevent serious infection in
CGD does not warrant its use in all patients. Again, these are
issues that could be addressed better by collecting data in a
prospective fashion.
The lack of an adequate time scale also complicates a proper
description of the first presenting signs, which would be of great
value for the training of physicians in order to recognize CGD and
to initiate proper diagnostic testing.
Clinicians have noted, and reported, a milder clinical course for
AR CGD patients leading to longer survival as compared to XL
CGD patients for many years [32]. Owing to the small number of
CGD patients, it has been difficult in the past to substantiate this
claim. The data presented in this paper have confirmed earlier
reports and show a clear statistically significant difference in life
span between the two main types of CGD, although it is important
to keep in mind that there have been individual AR-CGD patients
with early and extremely severe expression of the disease. It is not
clear why AR CGD in general follows a milder course, although
residual NADPH-oxidase activity has been shown in p47
phox
deficiency [33–34]. A difference in bactericidal activity of
neutrophils from the two groups has so far not been shown. From
this cohort, an increased susceptibility to one particular pathogen
in XL CGD patients was not apparent.
The isolated micro-organisms roughly correspond to the
pathogens known to be important in CGD [1–3]. However, many
cultures remained negative, perhaps owing to previous long-term
antibiotic/antifungal prophylactic therapy. A remarkable finding
was the relative paucity of Burkholderia cepacia as an important
pathogen in CGD. Further analysis of prospectively collected data
may clarify whether Burkholderia cepacia is indeed less frequently
found in CGD in Europe as compared to the United States and
the UK [1,3]. The severity of infection with Burkholderia cepacia was
examplified by the high percentage of lethal cases. Three patients
out of seven established infections with B. cepacia had died
(Tables 15 and 17). However, as a cause of death, Aspergillus spp.
stand at the top, warranting an even more aggressive approach to
this infection in CGD patients. Most clinical data are from a time
when dagnostic tools such as high resolution CT-scans and MRI
were not available. Also, many succesful anti-fungals currently in
use, such as voriconazole [27,35] or posaconazole [36], had at the
time not yet been developed. Better diagnosis and treatment
should lead to a reduction in Aspergillus-related mortality in the
future.
Our data also confirm an increased susceptibility to BCG-itis in
CGD patients, as has been recently described [24,25]. This newly
described feature warrants further investigation. It could be that a
hampered oxidative burst in macrophages complicates an
adequate clearance of the weak BCG pathogen, thus leading to
prolonged inflammatory activity.
Although the median life expectancy in this study was relatively
high (37.8 years for XL patients, 49.6 years for AR patients,
Table 4), and even better figures are to be expected for the future,
CGD remains a clinical challenge. Prophylactic treatment was not
taken by a large percentage of the patients (Table 16). Adequate
support, consisting of regular check-ups by a committed physician,
prophylactic treatment and prompt intervention when infection is
suspected remain the cornerstone of the treatment of CGD. The
development of new therapeutical strategies, such as gene therapy,
could also improve outcome [30,37].
In conclusion, the many data collected from this cohort broadly
confirm earlier assumptions on the clinical course and causative
pathogens of CGD. Further investigations should be performed in
a prospective manner, including data from more European
countries.
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